Hardman Johnston Global Advisors LLC Has $2.25 Million Stake in Fresenius Medical Care AG & Co. (FMS)

Hardman Johnston Global Advisors LLC increased its holdings in Fresenius Medical Care AG & Co. (NYSE:FMS) by 2.3% in the first quarter, HoldingsChannel reports. The institutional investor owned 55,390 shares of the company’s stock after buying an additional 1,250 shares during the period. Hardman Johnston Global Advisors LLC’s holdings in Fresenius Medical Care AG & Co. were worth $2,245,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in FMS. Lester Murray Antman dba SimplyRich acquired a new position in shares of Fresenius Medical Care AG & Co. during the first quarter valued at about $571,000. Renaissance Group LLC raised its holdings in shares of Fresenius Medical Care AG & Co. by 33.3% during the first quarter. Renaissance Group LLC now owns 377,246 shares of the company’s stock valued at $15,290,000 after purchasing an additional 94,236 shares during the period. Osborn Williams & Donohoe LLC acquired a new position in shares of Fresenius Medical Care AG & Co. during the first quarter valued at about $42,000. Duff & Phelps Investment Management Co. acquired a new position in shares of Fresenius Medical Care AG & Co. during the first quarter valued at about $3,677,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in shares of Fresenius Medical Care AG & Co. during the first quarter valued at about $231,000. Institutional investors own 1.90% of the company’s stock.

Shares of NYSE FMS opened at $41.17 on Friday. Fresenius Medical Care AG & Co. has a 1-year low of $30.99 and a 1-year high of $53.40. The stock has a market cap of $26.24 billion, a PE ratio of 18.14, a P/E/G ratio of 2.91 and a beta of 1.40. The company has a current ratio of 1.02, a quick ratio of 0.79 and a debt-to-equity ratio of 0.73.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its earnings results on Thursday, May 2nd. The company reported $0.59 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.07. Fresenius Medical Care AG & Co. had a net margin of 11.94% and a return on equity of 10.27%. The company had revenue of $4.13 billion for the quarter, compared to analyst estimates of $4.58 billion. During the same quarter in the prior year, the business posted $0.91 EPS. The firm’s revenue was up 3.9% compared to the same quarter last year. Equities analysts anticipate that Fresenius Medical Care AG & Co. will post 2.36 EPS for the current year.

The firm also recently announced an annual dividend, which will be paid on Friday, May 31st. Investors of record on Monday, May 20th will be issued a $0.6551 dividend. This represents a dividend yield of 1.59%. The ex-dividend date is Friday, May 17th. This is a positive change from Fresenius Medical Care AG & Co.’s previous annual dividend of $0.44. Fresenius Medical Care AG & Co.’s dividend payout ratio is currently 18.94%.

Several equities analysts have recently weighed in on the stock. DZ Bank reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a report on Tuesday. Commerzbank reiterated a “hold” rating and set a $54.00 price objective on shares of Fresenius Medical Care AG & Co. in a report on Thursday. Zacks Investment Research upgraded shares of Fresenius Medical Care AG & Co. from a “sell” rating to a “hold” rating in a report on Wednesday. Royal Bank of Canada reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a report on Monday, March 18th. Finally, SunTrust Banks upped their price objective on shares of Fresenius Medical Care AG & Co. to $48.00 and gave the company a “positive” rating in a report on Thursday, February 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. Fresenius Medical Care AG & Co. currently has an average rating of “Hold” and an average target price of $61.33.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/05/10/hardman-johnston-global-advisors-llc-has-2-25-million-stake-in-fresenius-medical-care-ag-co-fms.html.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Story: Cost of Equity

Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care AG & Co. (NYSE:FMS).

Institutional Ownership by Quarter for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.